Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
Tóm tắt
Currently, 68Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most widely used class of 68Ga radiotracers for PET, although DOTA is not optimal for 68Ga complexation. More recently, 1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly triazacyclononane-phosphinate (TRAP) chelators have been shown to possess superior 68Ga binding ability. Here, we report on the efficiency, reproducibility, and achievable specific activity for fully automated 68Ga labeling of DOTA-, NOTA-, and TRAP-peptide conjugates. Compared to NOTA- and DOTA-peptides, achievable specific activity (A
S) for TRAP-peptide is approximately 10 and 20 times higher, respectively. A
S values in the range of 5,000 GBq/μmol were routinely obtained using 1 GBq of 68Ga, equivalent to 0.11 μg of cold mass for a 185-MBq patient dose of a 3-kDa conjugate. The TRAP-peptide could be 68Ga-labeled with excellent reproducibility and > 95% radiochemical yield for precursor amounts as low as 1 nmol. High 68Ga labeling efficiency of TRAP-peptides could facilitate realization of kit labeling procedures. The good reproducibility of the automated synthesis is of relevance for GMP production, and the possibility to provide very high specific activities offers a high degree of safety in first clinical trials, due to reduction of cold mass content in tracer formulations.
Tài liệu tham khảo
Decristoforo C, Pickett RD, Verbruggen A: Feasibility and availability of 68 Ga-labelled peptides. Eur J Nucl Med Mol Imaging 2012, 39: S31-S40. 10.1007/s00259-011-1988-5
Fani M, André JP, Maecke HR: 68 Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008, 3: 67–77.
Bartholomä MD, Louie AS, Valliant JF, Zubieta J: Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem Rev 2010, 110: 2903–2920. 10.1021/cr1000755
Ballinger JR: 99 Mo shortage in nuclear medicine: crisis or challenge? J Label Compd Radiopharm 2010, 53: 167–168.
Notni J, Hermann P, Havlíčková J, Kotek J, Kubíček V, Plutnar J, Loktionova N, Riss PJ, Rösch F, Lukeš I: A triazacyclononane-based bifunctional phosphinate ligand for the preparation of multimeric 68 Ga tracers for positron emission tomography. Chem Eur J 2010, 16: 7174–7185.
Notni J, Šimeček J, Hermann P, Wester HJ: TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem Eur J 2011, 17: 14718–14722. 10.1002/chem.201103503
Šimeček J, Schulz M, Notni J, Plutnar J, Kubíček V, Havlíčková J, Hermann P: Complexation of metal ions with TRAP (1,4,7-triazacyclononane phosphinic acid) ligands and NOTA: phosphinate-containing ligands as unique chelators for trivalent gallium. Inorg Chem 2012, 51: 577–590. 10.1021/ic202103v
Notni J, Plutnar J, Wester HJ: Bone seeking TRAP conjugates: surprising observations and implications on development of gallium-68-labeled bisphosphonates. EJNMMI Res 2012, 2: 13. 10.1186/2191-219X-2-13
Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ: 68 Ga-NODAGA-RGD is a suitable substitute for 18 F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process . Nucl Med Biol 2012. 10.1016/j.nucmedbio.2012.02.006
Kubíček V, Havlíčková J, Kotek J, Tircsó G, Hermann P, Tóth E, Lukeš I: Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermodynamic studies. Inorg Chem 2010, 49: 10960–10969. 10.1021/ic101378s
Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN: A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004, 45: 116–123.
Breeman WAP, Kwekkeboom DK, Kooij PPM, Bakker WH, Hofland LJ, Visser TJ, Ensing GJ, Lamberts SWJ, Krenning EP: Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995, 36: 623–627.
de Jong M, Breeman WAP, Bernard BF, van Gameren A, de Bruin E, Bakker WH, van der Pluijm ME, Visser TJ, Mäcke HR, Krenning EP: Tumour uptake of the radiolabelled somatostatin analogue [DOTA0 , TYR3 ]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999, 26: 693–698. 10.1007/s002590050439
Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, Långström B: In vivo binding of [68 Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours—impact of peptide mass. Nucl Med Biol 2010, 37: 265–275. 10.1016/j.nucmedbio.2009.11.008
Simecek J, Zemek O, Hermann P, Wester HJ, Notni J: A monoreactive bifunctional triazacyclononane-phosphinate chelator with high selectivity for gallium-68. Chem Med Chem 2012. 10.1002/cmdc.201200261